Skip to main content

Table 5 Medications in women with HFrEF and HFpEF subgroups

From: Clinical characteristics and in-hospital outcome of heart failure in women: a single center registry from Egyptian cardiac care unit

 HFrEF, n = 73HFpEF, n = 45P value
Thazides5 (6.85%)3 (6.7%)0.969
Loop diuretics40 (54.8%)28 (62.22%)0.428
Nitrates39 (53.4%)28 (62.22%)0.349
Warfarin17 (23.3%)14 (31.11%)0.348
Clopidogril41 (56.2%)17 (37.8%)0.052
CCB2 (2.74%)6 (13.33%)0.026
Amiodarone10 (13.7%)7 (15.6%)0.780
Unfractunated heparin19 (26.02%)15 (33.33%)0.395
LMWH52 (71.23%)27 (60%)0.208
Lytic therapy24 (32.88%)8 (17.8%)0.073
Aldosterone antagonist32 (43.8%)18 (40%)0.682
Digixon19 (26.03%)13 (28.9%)0.734
PPIH blockers55 (75.34%)42 (93.3%)0.013
Warfarin A10 (13.7%)12 (26.7%)0.079
ASA60 (82.2%)28 (62.22%)0.016
Beta-blockers27 (37%)18 (40%)0.743
ACEI38 (52.1%)22 (49%)0.738
ARBs8 (11%)10 (22.22%)0.098
Statin58 (79.5%)32 (71.1%)0.301
  1. CCB calcium channel blockers, LMWH low molecular weight heparin, ASA acetyl salsylic acid, ACEI angiotensin converting enzyme inhibitor, ARBS angiotensin receptor blockers